Rationale
Psychostimulants, such as yohimbine and amphetamine, can enhance learning and memory. Extinction of conditioned fear involves
new learning, so we asked whether psychostimulants could enhance this learning. Previous work suggests that yohimbine facilitates
extinction, using freezing as a fear measure. However, psychostimulant-induced alterations in locomotion can confound freezing
measurements. Furthermore, the effects of amphetamine on fear extinction have never been examined.
Objective
We evaluated the effectiveness of yohimbine and amphetamine in enhancing fear extinction. In addition to freezing, we measured
bar-press suppression, which is less sensitive to changes in locomotion. We asked: Do psychostimulants reduce fear during
extinction training when drug is present? Does learning extinction with psychostimulants result in better extinction retention?
Materials and methods
Rats received fear conditioning on day 1 followed by partial extinction training on days 2 and 3. Yohimbine (1.0, 2.0, or
5.0 mg/kg, i.p.), amphetamine (1.0 mg/kg, i.p.), or vehicle were injected prior to extinction on day 2.
Results
Yohimbine dose-dependently reduced freezing during extinction training on day 2, whereas bar-press suppression was reduced
at the highest dose only. When tested drug-free, yohimbine-treated rats showed equivalent levels of freezing and suppression
to controls. Amphetamine also decreased freezing during extinction, but did not decrease suppression. During the drug-free
test, there was no difference between amphetamine-treated rats and controls in either measure.
Conclusions
Although yohimbine and amphetamine are capable of decreasing freezing, neither drug strengthened retention of fear extinction.
Based on these rodent findings, psychostimulants may not be suitable adjuncts to extinction-based therapies for the treatment
of anxiety disorders.
Keywords Fear conditioning - Psychostimulant - Norepinephrine - Fear extinction - Bar-press suppression - Freezing - α2-Adrenoceptor antagonist - Reuptake blocker - Anxiety disorders
Devin Mueller and Lening A. Olivera-Figueroa contributed equally to this work.